CAR-T/CAR-NK Cells Development for Drug Delivery Systems

CAR-T/CAR-NK Cells Development for Drug Delivery Systems

CD Formulation, as a provider of services and products for drug delivery, can offer you high-quality services and products. The basic structure of a CAR consists of a tumor-associated antigen (TAA) binding region (usually derived from the scFV segment of the monoclonal antibody antigen binding region), a hinge area, a transmembrane region and the Immunoreceptor tyrosine-based activation motif (ITAM).  CD Formulation is dedicated to the discovery and design development of drug delivery systems, and we are confident that we can provide the best service and products to our customers around the world.

What is a CAR?

Chimeric antigen receptors (CARs) are synthetic modular proteins that redirect immune cells in response to target antigens expressed on malignant cells. This flexible platform has shown significant clinical efficacy in the treatment of B-cell and plasma cell malignancies, and as such, the potential for application of this therapy is driving rapid advances in technology and large-scale investments from academia and the biopharmaceutical industry. Modifications to the CAR prototype design allow for some adjustment of antigen density thresholds, where modulation of signal strength, scFv affinity, CAR expression density, hinge/transmembrane structure, and synaptic spacing characteristics can all have important implications.

Cells Development

CD Formulation provides development services for CAR-T cells and CAR-NK cells, providing large mold manufacturing method improvements, storage optimization and efficacy enhancement services in addition to its own drug delivery enhancements.

CAR-T cells are live drugs with proliferative capabilities and unique cellular kinetic properties. Traditional pharmacokinetic parameters and pharmacokinetic models are not applicable to CAR-T cells due to antigen-dependent amplification, infusion product heterogeneity, and tumor microenvironment.

Our team can design to co-embed immunostimulatory signals with CAR-T cells, which will enhance local t-cell expansion after in vivo administration. The self-assembled, entropy-driven cross-linking in these PNP hydrogels yields temperature-invariant mechanical properties, and their physical cross-linking can be easily injected via needle or catheter.

CAR-modified NK cells can provide an alternative "off-the-shelf" vector for CAR-based therapies and deliver more targeted drugs to tumor sites through surface engineering. NK cells are identical to parental cell lines, eliminating the problem of donor variation. The use of surface-engineered CAR-NK cells for targeted drug delivery has broad applicability.

NK cells are genetically engineered to express chimeric antigen receptors, which can enhance the tumor-specific killing effect of NK cells. By using modified NK cells as carriers for targeted nanodrug delivery and targeting drug-laden nanoparticles to the target, the efficacy of chemotherapy can be enhanced in vitro and in vivo while reducing off-target toxicity.

With years of experience in drug delivery development, CD Formulation has been providing fully customized solutions to our partners and supporting the development of new therapies to improve lives. Our CAR cell therapy experts have built on advanced technologies for CAR cell development and associated biochemical testing.

If you need a service that is not on our list, please feel free to contact us. Our team of professionals will customize services and solutions exclusively for your project.

Online Inquiry
Please note: Our products and services are not intended to be used directly in diagnostic or therapeutic procedures.
Enter your email here to subscribe.

Easy access to products and services you need from our library via powerful searching tools.

Copyright © CD Formulation. All Rights Reserved.  Privacy Policy | Cookie Policy